GENELUX Corp
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
GNLX$1.95-5.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2025 | 2024 | |
| Cash Flows from operating activities | ||
| Net loss | $(22,898) | $(20,893) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 184 | 178 |
| Net amortization of premiums and discounts on short-term investments | (188) | (556) |
| Right-of-use asset | 242 | 498 |
| Stock compensation | 4,336 | 4,308 |
| Fair value of restricted stock units | 578 | 1,352 |
| Cost of stock option modifications and repricing | 738 | 326 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (13) | (568) |
| Accounts payable and accrued expenses | (1,587) | 340 |
| Accrued payroll and payroll taxes | (217) | (1,431) |
| Lease liability | (244) | (480) |
| Net cash used in operating activities | (19,069) | (16,926) |
| Cash Flows from investing activities | ||
| Purchases of property and equipment | (662) | (285) |
| Purchase of investments | (18,261) | (28,520) |
| Proceeds from maturities of investments | 24,500 | 14,000 |
| Net cash provided by (used in) investing activities | 5,577 | (14,805) |
| Cash Flows from financing activities | ||
| Proceeds from common stock issued for Company equity award | 52 | 49 |
| Proceeds from the exercise of stock options | 14 | 688 |
| Proceeds from common stock issued | 9,553 | 27,678 |
| Net cash provided by financing activities | 9,619 | 28,415 |
| Net decrease in cash, cash equivalents and restricted cash | (3,873) | (3,316) |
| Cash, cash equivalents and restricted cash | ||
| Beginning of period | 8,565 | 9,418 |
| End of period | $4,692 | $6,102 |
| Supplemental non-cash financing disclosures: | ||
| Unrealized (loss) gain on investments | $(56) | $110 |
| Accrual of other receivable | - | 330 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.